JP2002523449A - ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法 - Google Patents
ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法Info
- Publication number
- JP2002523449A JP2002523449A JP2000567193A JP2000567193A JP2002523449A JP 2002523449 A JP2002523449 A JP 2002523449A JP 2000567193 A JP2000567193 A JP 2000567193A JP 2000567193 A JP2000567193 A JP 2000567193A JP 2002523449 A JP2002523449 A JP 2002523449A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- nitric oxide
- composition
- group
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D459/00—Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/145,143 US6294517B1 (en) | 1996-02-02 | 1998-09-01 | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| US09/145,143 | 1998-09-01 | ||
| PCT/US1999/020023 WO2000012075A1 (en) | 1998-09-01 | 1999-09-01 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002523449A true JP2002523449A (ja) | 2002-07-30 |
| JP2002523449A5 JP2002523449A5 (US06294517-20010925-C00024.png) | 2006-10-19 |
Family
ID=22511778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000567193A Pending JP2002523449A (ja) | 1998-09-01 | 1999-09-01 | ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法 |
Country Status (6)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5004215B2 (ja) * | 2004-03-05 | 2012-08-22 | キッセイ薬品工業株式会社 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786101B1 (fr) * | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
| AU6124401A (en) | 2000-05-09 | 2001-11-20 | Nitromed Inc | Infrared thermography and methods of use |
| EP1383502A4 (en) * | 2001-03-06 | 2007-07-25 | Strakan Int Ltd | COMPOUNDS AND METHOD FOR TREATING UROGENITAL DISORDER |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
| US20030158184A1 (en) * | 2001-12-21 | 2003-08-21 | Garvey David S. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| WO2003086282A2 (en) * | 2002-04-05 | 2003-10-23 | Nitromed, Inc. | Nitric oxide donors, compositions and methods of use |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| WO2004071437A2 (en) * | 2003-02-07 | 2004-08-26 | Barmensen, Inc. | Compositions for enhancing sexual responsiveness |
| WO2004071533A1 (ja) * | 2003-02-14 | 2004-08-26 | Takeda Pharmaceutical Company Limited | 局所投与用製剤 |
| EP1471066A1 (en) * | 2003-04-24 | 2004-10-27 | Aventis Pharma Deutschland GmbH | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals |
| US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
| FR2856592B1 (fr) * | 2003-06-27 | 2008-04-25 | Oreal | Composition cosmetique a base de percuseur(s) de radical thiyl pour la deformation permanente des fibres keratiniques |
| US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| SE0402221D0 (sv) * | 2004-09-14 | 2004-09-14 | Aerocrine Ab | Treatment of insufficient perfusion |
| US9107917B2 (en) * | 2005-05-13 | 2015-08-18 | The Feinstein Institute For Medical Research | Treatment of sepsis and inflammation with alpha2A adrenergic antagonists |
| JP5274248B2 (ja) | 2005-05-27 | 2013-08-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子 |
| US9045505B2 (en) | 2006-09-28 | 2015-06-02 | University Of Otago | Nitric oxide donors |
| US7807716B2 (en) * | 2008-09-24 | 2010-10-05 | Oral Delivery Technology Ltd. | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use |
| US20100098733A1 (en) * | 2008-10-16 | 2010-04-22 | Novan, Inc. | Nitric oxide releasing particles for oral care applications |
| WO2010110684A1 (en) * | 2009-03-27 | 2010-09-30 | Robin Andrew James Smith | Nitric oxide donors |
| US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
| EP2467173B8 (en) | 2009-08-21 | 2019-06-19 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| CN102782056A (zh) * | 2009-10-13 | 2012-11-14 | 诺万公司 | 一氧化氮-释放性涂层 |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| EP2681286B1 (en) | 2011-02-28 | 2018-08-15 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
| JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
| KR102476626B1 (ko) | 2014-11-14 | 2022-12-09 | 폴리 인터내셔널 | 탈모증을 예방하기 위한 시스템 및 방법 |
| ES2904543T3 (es) | 2015-06-11 | 2022-04-05 | ReJoy | Tratamiento de la disfunción sexual |
| US11186564B2 (en) * | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
| WO2018073821A1 (en) * | 2016-10-18 | 2018-04-26 | Vasolead (2012) Ltd. | Compositions and methods for treating erectile dysfunction |
| CN108464971A (zh) * | 2018-07-02 | 2018-08-31 | 福州脉趣恒生科技有限公司 | 一种含有斯诺普利的抗高血压口服片剂及其制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| FR2547501A1 (fr) | 1983-06-15 | 1984-12-21 | Opochimiotherapie Lab | Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants |
| US4885173A (en) | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| IT1221826B (it) | 1988-06-08 | 1990-07-12 | Medico Harvey Srl Centro | Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US5059603A (en) | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
| FR2649613B1 (fr) | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
| US5236904A (en) | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| GB9012469D0 (en) | 1990-06-05 | 1990-07-25 | Glaxo Group Ltd | Medicaments |
| US5399581A (en) | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| DE4117249C2 (de) | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
| AU3071592A (en) | 1991-11-14 | 1993-06-15 | Brigham And Women's Hospital | Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality |
| AU3237193A (en) | 1991-12-11 | 1993-07-19 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| US5646181A (en) | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
| US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| ATE190843T1 (de) | 1993-02-10 | 2000-04-15 | Bmra Corp Bv | Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten |
| US5439938A (en) | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
| US5698589A (en) | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| US5543430A (en) | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
| US5583144A (en) | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
| US5612314A (en) | 1995-04-21 | 1997-03-18 | Brigham & Women's Hospital | Nitrosylated neuropeptides |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| US5789442A (en) | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| US5994294A (en) | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US5932538A (en) | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| GB9608408D0 (en) | 1996-04-23 | 1996-06-26 | Adams Michael A | Treatment of erectile dysfunction |
| JPH1026962A (ja) | 1996-07-11 | 1998-01-27 | Hitachi Ltd | 情報処理装置 |
| FR2765483B1 (fr) | 1997-07-04 | 2000-02-04 | Philippe Gorny | Medicament destine a traiter les dysfonctions erectiles |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| FR2774593B1 (fr) | 1998-02-12 | 2000-05-05 | Philippe Gorny | Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines |
| US6277884B1 (en) * | 1998-06-01 | 2001-08-21 | Nitromed, Inc. | Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
-
1998
- 1998-09-01 US US09/145,143 patent/US6294517B1/en not_active Expired - Fee Related
-
1999
- 1999-03-30 US US09/280,540 patent/US6514934B1/en not_active Expired - Fee Related
- 1999-05-07 US US09/306,805 patent/US6433182B1/en not_active Expired - Fee Related
- 1999-05-07 US US09/306,809 patent/US6417162B1/en not_active Expired - Fee Related
- 1999-09-01 CA CA002339145A patent/CA2339145A1/en not_active Abandoned
- 1999-09-01 WO PCT/US1999/020023 patent/WO2000012075A1/en active IP Right Grant
- 1999-09-01 JP JP2000567193A patent/JP2002523449A/ja active Pending
- 1999-09-01 AU AU57016/99A patent/AU770414B2/en not_active Ceased
- 1999-09-01 EP EP99944040A patent/EP1109542A4/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5004215B2 (ja) * | 2004-03-05 | 2012-08-22 | キッセイ薬品工業株式会社 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US6417162B1 (en) | 2002-07-09 |
| CA2339145A1 (en) | 2000-03-09 |
| US6514934B1 (en) | 2003-02-04 |
| US6294517B1 (en) | 2001-09-25 |
| AU770414B2 (en) | 2004-02-19 |
| AU5701699A (en) | 2000-03-21 |
| US6433182B1 (en) | 2002-08-13 |
| EP1109542A1 (en) | 2001-06-27 |
| WO2000012075A1 (en) | 2000-03-09 |
| EP1109542A4 (en) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002523449A (ja) | ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法 | |
| US6693122B2 (en) | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | |
| US6331543B1 (en) | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | |
| US20050187222A1 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | |
| AU773269B2 (en) | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | |
| US7772278B2 (en) | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | |
| AU722480B2 (en) | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | |
| EP1852422A2 (en) | Nitrosated and nitorsylated alpha-andrenergic receptor antagonist compounds, compositions and their uses | |
| EP1018879A1 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | |
| WO1998019672A9 (en) | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | |
| US6469065B1 (en) | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use | |
| US20020061879A1 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | |
| US20050065161A1 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | |
| AU2004201585B2 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | |
| US20030158184A1 (en) | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | |
| US20060063774A1 (en) | Phosphodiesterase inhibitor compounds and nitric oxide donors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090317 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091013 |